U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07387198) titled 'Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab' on Jan. 28.
Brief Summary: The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Merkel Cell Carcinoma, Stage I
Merkel Cell Carcinoma, Stage II
Neoadjuvant Immunotherapy
Intervention:
DRUG: Cemiplimab 350 mg i....